The Middle East and Africa generic injectables market was valued at USD 0.97 Billion in 2025, driven by the growing demand for cost-effective healthcare solutions and growth in local generic manufacturing capabilities in the region. The market is expected to grow at a CAGR of 7.80% during the forecast period of 2026-2035, reaching a value of USD 2.06 Billion by 2035.
Base Year
Historical Period
Forecast Period
The Middle Eastern and African countries are heavily investing in the healthcare and pharmaceutical sectors which directly impacts the production of low-cost generic injectable products.
The rising innovations in formulations of faster-acting injectable generics in oncology and specialty therapeutic areas are poised to fuel the Middle East and Africa generic injectables market demand.
One of the major market trends is the increase in public-private partnerships to accelerate the availability of affordable generic injectables in low-income countries.
Compound Annual Growth Rate
7.8%
Value in USD Billion
2026-2035
*this image is indicative*
Generic injectables are high-quality bioequivalent versions of expensive innovator injectables, typically marketed at a lower price. These pharmaceutical products are injected either by a healthcare worker or the patients themselves and are used in certain clinical settings such as cancer care, trauma, and surgery, due to their rapid onset of action and higher bioavailability. There is a growing focus on the development of novel formulations of these faster-acting generics in oncology and specialty therapeutic areas, which is influencing the global generic injectables market landscape. Further, several generic manufacturers are increasingly investing in expanding their generic injectable portfolio to meet the growing healthcare demand, which is expected to fuel the Middle East and Africa generic injectables market growth.
The Middle Eastern and African countries are heavily investing in the healthcare and pharmaceutical sectors which has substantially affected the market demand. Recent data reveals that the size of the pharmaceutical market in Saudi Arabia has witnessed a massive increase, with most of the national pharmaceutical industries focused on the production of generics. Additionally, local manufacturing of generic injectables was estimated to be 30% out of all dosage forms in the region. This growth of local generic pharmaceutical manufacturing capabilities and capacities, supported by both public and private investments, is projected to boost the Middle East and Africa generic injectables market share.
One of the major market trends is the rise in strategic partnerships between public and private bodies to address global health challenges. For instance, in March 2023 , multinational pharmaceutical company GlaxoSmithKline (GSK plc) issued voluntary licenses to three companies (Aurobindo Pharma, Cipla, and Viatris) to manufacture generic versions of its HIV preventive medicine (injectable drug cabotegravir). This deal is likely to expedite market penetration of this injectable in lower-income countries. Further, Indian drugmaker Cipla reported plans to manufacture the generic injection in South Africa. Moreover, GSK also announced a public-private partnership with the Medicines Patent Pool (a United Nations-backed healthcare organization) in July 2022, to accelerate access to new HIV therapies in poor countries, with the introduction of its generic injectables expected by 2026. Such licensing agreements indicate an emphasis on increasing access to cost-effective medications which is anticipated to elevate the market value in the forecast period.
The EMR’s report titled “Middle East and Africa Generic Injectables Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
Market Breakup by Container Type
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Pfizer has a strong presence in the sterile injectables industry, with a range of offerings in generic and branded products. To expand its market presence in the generic injectables sector, it acquired a leading manufacturer of injectable drugs and infusion technologies, Hospira, in 2015.
A global leader in generic injectables, Baxter International Inc., is actively engaged in strategic mergers and acquisition activities to bolster the development of generic injectables in various therapeutic categories.
This British multinational pharmaceutical company is known for its non-branded generic and in-licensed products. It is a leading supplier of injectable pharmaceuticals in the Middle East and North African countries and is focusing on expanding local manufacturing operations in the region.
Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company, is a prominent player in the market. It specializes in developing generic formulations, including injectables, tablets, capsules, and topical creams across the major therapeutic areas.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Viatris Inc., and Sanofi, among others.
Upto 15% Off
USD
$4299 $3869
$2699 $2429
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 0.97 Billion in 2025 driven by the growth in local generic manufacturing capabilities in the region.
The market is anticipated to grow at a CAGR of 7.80% during the forecast period of 2026-2035, likely to reach a market value of USD 2.06 Billion by 2035.
The rising investment in healthcare infrastructure and the growing healthcare needs are fuelling the demand for the market.
One of the significant trends in the market is the increase in public-private partnerships to accelerate the availability of affordable generic injectables in low-income countries. In July 2022, GSK plc announced one such strategic partnership with the Medicines Patent Pool to accelerate access to new HIV therapies in poor countries, with the introduction of its generic injectables expected by 2026.
Based on the product type, the market is segmented into large molecule injectables and small molecule injectables.
Container types available in the market include vials, premix, prefilled syringes, and ampoules, among others.
Major applications include oncology, cardiovascular, CNS, infectious diseases, and autoimmune disorders, among others.
The market breakup by route of administration includes intravenous, intramuscular, and subcutaneous, among others.
Distribution channels of the market are hospitals and retail pharmacies, among others.
The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.
The key players in the market are Pfizer Inc., Baxter, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Viatris Inc., and Sanofi.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Container Type |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share